Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research report sent to investors on Wednesday, TipRanks reports. HC Wainwright currently has a $4.00 price objective on the stock.

LCTX has been the subject of a number of other research reports. Maxim Group set a $3.00 target price on shares of Lineage Cell Therapeutics and gave the stock a buy rating in a research note on Tuesday, October 15th. Chardan Capital reissued a buy rating on shares of Lineage Cell Therapeutics in a research note on Thursday, August 22nd. Zacks Investment Research downgraded shares of Lineage Cell Therapeutics from a hold rating to a sell rating in a research note on Thursday, October 10th. Finally, ValuEngine raised shares of Lineage Cell Therapeutics from a strong sell rating to a sell rating in a research note on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $2.67.

NYSEAMERICAN LCTX traded up $0.07 during mid-day trading on Wednesday, reaching $0.87. 747,921 shares of the stock were exchanged, compared to its average volume of 613,741. Lineage Cell Therapeutics has a one year low of $0.66 and a one year high of $1.87. The company has a 50 day moving average of $0.98.

Institutional investors and hedge funds have recently bought and sold shares of the business. Moors & Cabot Inc. bought a new stake in Lineage Cell Therapeutics in the third quarter valued at $34,000. California Public Employees Retirement System bought a new stake in Lineage Cell Therapeutics in the third quarter valued at $47,000. Commonwealth Equity Services LLC bought a new stake in Lineage Cell Therapeutics in the third quarter valued at $112,000. Rhumbline Advisers bought a new stake in Lineage Cell Therapeutics in the third quarter valued at $177,000. Finally, Creative Planning bought a new stake in Lineage Cell Therapeutics in the third quarter valued at $201,000.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Recommended Story: The risks of owning bonds

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.